[1] |
SERIOLO B, PAOLINO S, CASABELLA A, et al. Osteoporosis in the elderly[J]. Aging Clin Exp Res, 2013, 25( Suppl 1): S27- S29. DOI: 10.1007/s40520-013-0107-9.
|
[2] |
ABBASI M, FARZAM SA, MAMAGHANI Z, et al. Relationship between metabolic syndrome and its components with bone densitometry in postmenopausal women[J]. Diabetes Metab Syndr, 2017, 11( Suppl 1): S73- S76. DOI: 10.1016/j.dsx.2016.12.008.
|
[3] |
SHANBHOGUE VV, FINKELSTEIN JS, BOUXSEIN ML, et al. Association between insulin resistance and bone structure in nondiabetic postmenopausal women[J]. J Clin Endocrinol Metab, 2016, 101( 8): 3114- 3122. DOI: 10.1210/jc.2016-1726.
|
[4] |
National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology. Guidelines for management of nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2010, 26( 2): 120- 124.
中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南[J]. 临床肝胆病杂志, 2010, 26( 2): 120- 124.
|
[5] |
JIN R, WANG XX, LIU F, et al. Research advances in pharmacotherapy for nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2022, 38( 7): 1634- 1640. DOI: 10.3969/j.issn.1001-5256.2022.07.033.
靳睿, 王晓晓, 刘峰, 等. 非酒精性脂肪性肝病的药物治疗进展[J]. 临床肝胆病杂志, 2022, 38( 7): 1634- 1640. DOI: 10.3969/j.issn.1001-5256.2022.07.033.
|
[6] |
PAN BJ, CAI J, ZHAO PP, et al. Relationship between prevalence and risk of osteoporosis or osteoporotic fracture with non-alcoholic fatty liver disease: A systematic review and meta-analysis[J]. Osteoporos Int, 2022, 33( 11): 2275- 2286. DOI: 10.1007/s00198-022-06459-y.
|
[7] |
CUI R, SHENG H, RUI XF, et al. Low bone mineral density in Chinese adults with nonalcoholic fatty liver disease[J]. Int J Endocrinol, 2013, 2013: 396545. DOI: 10.1155/2013/396545.
|
[8] |
MOON SS, LEE YS, KIM SW. Association of nonalcoholic fatty liver disease with low bone mass in postmenopausal women[J]. Endocrine, 2012, 42( 2): 423- 429. DOI: 10.1007/s12020-012-9639-6.
|
[9] |
UPALA S, JARUVONGVANICH V, WIJARNPREECHA K, et al. Nonalcoholic fatty liver disease and osteoporosis: A systematic review and meta-analysis[J]. J Bone Miner Metab, 2017, 35( 6): 685- 693. DOI: 10.1007/s00774-016-0807-2.
|
[10] |
MANTOVANI A, DAURIZ M, GATTI D, et al. Systematic review with meta-analysis: Non-alcoholic fatty liver disease is associated with a history of osteoporotic fractures but not with low bone mineral density[J]. Aliment Pharmacol Ther, 2019, 49( 4): 375- 388. DOI: 10.1111/apt.15087.
|
[11] |
KAYA M, IŞıK D, BEŞTAŞ R, et al. Increased bone mineral density in patients with non-alcoholic steatohepatitis[J]. World J Hepatol, 2013, 5( 11): 627- 634. DOI: 10.4254/wjh.v5.i11.627.
|
[12] |
VACHLIOTIS ID, ANASTASILAKIS AD, GOULAS A, et al. Nonalcoholic fatty liver disease and osteoporosis: A potential association with therapeutic implications[J]. Diabetes Obes Metab, 2022, 24( 9): 1702- 1720. DOI: 10.1111/dom.14774.
|
[13] |
MARCUCCI G, DOMAZETOVIC V, NEDIANI C, et al. Oxidative stress and natural antioxidants in osteoporosis: Novel preventive and therapeutic approaches[J]. Antioxidants(Basel), 2023, 12( 2): 373. DOI: 10.3390/antiox12020373.
|
[14] |
SHI Y, LIU XY, JIANG YP, et al. Monotropein attenuates oxidative stress via Akt/mTOR-mediated autophagy in osteoblast cells[J]. Biomed Pharmacother, 2020, 121: 109566. DOI: 10.1016/j.biopha.2019.109566.
|
[15] |
SUN S, XU MH, ZHUANG PJ, et al. Effect and mechanism of vitamin D activation disorder on liver fibrosis in biliary atresia[J]. Sci Rep, 2021, 11: 19883. DOI: 10.1038/s41598-021-99158-3.
|
[16] |
DRAPKINA OM, ELKINA AY, SHEPTULINA AF, et al. Non-alcoholic fatty liver disease and bone tissue metabolism: Current findings and future perspectives[J]. Int J Mol Sci, 2023, 24( 9): 8445. DOI: 10.3390/ijms24098445.
|
[17] |
LIU W, YUAN J, SU ZY, et al. Relationship between bone metabolism and insulin resistance in male type 2 diabetes mellitus patients from community with different body mass indexes[J]. J Clin Intern Med, 2018, 35( 3): 173- 176. DOI: 10.3969/j.issn.1001-9057.2018.03.009.
刘薇, 原晶, 苏志燕, 等. 不同体重指数的社区男性2型糖尿病患者骨代谢与胰岛素抵抗的相关性研究[J]. 临床内科杂志, 2018, 35( 3): 173- 176. DOI: 10.3969/j.issn.1001-9057.2018.03.009.
|
[18] |
ZENG R, HUANG SY, LIAO SB. Study on the influential factors of lumbar osteoporosis in postmenopausal women with type 2 diabetes mellitus[J]. Chin J Osteoporos, 2021, 27( 11): 1620- 1625. DOI: 10.3969/j.issn.1006-7108.2021.11.012.
曾荣, 黄淑玉, 廖世波. 绝经后女性2型糖尿病患者腰椎骨质疏松的影响因素研究[J]. 中国骨质疏松杂志, 2021, 27( 11): 1620- 1625. DOI: 10.3969/j.issn.1006-7108.2021.11.012.
|
[19] |
GAO M, LI SL. The research progress in the relationship between serum uric acid and osteoporosis[J]. Chin J Osteoporos, 2016, 22( 5): 641- 646. DOI: 10.3969/j.issn.1006-7108.2016.05.026.
高萌, 李社莉. 血尿酸与骨质疏松症关系的研究进展[J]. 中国骨质疏松杂志, 2016, 22( 5): 641- 646. DOI: 10.3969/j.issn.1006-7108.2016.05.026.
|
[20] |
ZHAO N, LI SM, FANG XX, et al. Study of the relationship between bone mineral density and serum uric acid in senile diabetic patients[J]. Chin J Osteoporos, 2014, 20( 7): 784- 788. DOI: 10.3969/j.issn.1006-7108.2014.07.013.
赵娜, 李素梅, 方星星, 等. 老年糖尿病患者骨密度与血尿酸水平的相关研究[J]. 中国骨质疏松杂志, 2014, 20( 7): 784- 788. DOI: 10.3969/j.issn.1006-7108.2014.07.013.
|
[21] |
ESTEP M, ABAWI M, JARRAR M, et al. Association of obestatin, ghrelin, and inflammatory cytokines in obese patients with non-alcoholic fatty liver disease[J]. Obes Surg, 2011, 21( 11): 1750- 1757. DOI: 10.1007/s11695-011-0475-1.
|
[22] |
YAN DD, WANG J, HOU XH, et al. Association of serum uric acid levels with osteoporosis and bone turnover markers in a Chinese population[J]. Acta Pharmacol Sin, 2018, 39( 4): 626- 632. DOI: 10.1038/aps.2017.165.
|
[23] |
HAN W, BAI XJ, WANG N, et al. Association between lumbar bone mineral density and serum uric acid in postmenopausal women: A cross-sectional study of healthy Chinese population[J]. Arch Osteoporos, 2017, 12( 1): 50. DOI: 10.1007/s11657-017-0345-0.
|
[24] |
ZHANG BW, LEI T. Obesity and osteoporosis[J]. Int J Endocrinol Metab, 2010, 30( 4): 242- 244. DOI: 10.3760/cma.j.issn.1673-4157.2010.04.008.
张宝伟, 雷涛. 肥胖与骨质疏松[J]. 国际内分泌代谢杂志, 2010, 30( 4): 242- 244. DOI: 10.3760/cma.j.issn.1673-4157.2010.04.008.
|
[25] |
ASPRAY TJ, HILL TR. Osteoporosis and the ageing skeleton[J]. Subcell Biochem, 2019, 91: 453- 476. DOI: 10.1007/978-981-13-3681-2_16.
|
[26] |
FENG C, XU ZW, TANG XJ, et al. Estrogen-related receptor α: A significant regulator and promising target in bone homeostasis and bone metastasis[J]. Molecules, 2022, 27( 13): 3976. DOI: 10.3390/molecules27133976.
|
[27] |
MA YZ, WANG YP, LIU Q, et al. 2018 China guideline for the diagnosis and treatment of senile osteoporosis[J]. Chin J Gerontol, 2019, 39( 11): 2557- 2575. DOI: 10.3969/j.issn.1005-9202.2019.11.001.
马远征, 王以朋, 刘强, 等. 中国老年骨质疏松诊疗指南(2018)[J]. 中国老年学杂志, 2019, 39( 11): 2557- 2575. DOI: 10.3969/j.issn.1005-9202.2019.11.001.
|
[1] | Yuzhen YU, Liewang QIU, Ping HE. Association between Helicobacter pylori and nonalcoholic fatty liver disease: A Meta-analysis[J]. Journal of Clinical Hepatology, 2024, 40(7): 1360-1369. doi: 10.12449/JCH240713 |
[2] | Jingjie ZHAO, Xinyu ZHAO, Chaoru HAN, Kaihui XIAO, Zhengzhao LU, Linyan QIN, Dong XU, Hong YOU. Association between sleep disorders and different stages of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2024, 40(7): 1354-1359. doi: 10.12449/JCH240712 |
[3] | Lingwei LI, Junjie QIN, Yunlong JIA, Hao LYU. Application of Mendelian randomization in liver cancer[J]. Journal of Clinical Hepatology, 2024, 40(2): 391-396. doi: 10.12449/JCH240228 |
[4] | Wei HE, Shuke ZHU, Chunyu LI, Xue DU, Jiarui LI. Causal association of liver function and lipid metabolism levels with sleep disorders based on Mendelian randomization[J]. Journal of Clinical Hepatology, 2024, 40(10): 2055-2061. doi: 10.12449/JCH241020 |
[5] | Haoxin DUAN, Yuyong JIANG, Tingyu WU, Feixiang XIONG, Yandan JIANG, Qin ZHANG, Saisai ZHAO, Hao YU. The genetic association between nonalcoholic fatty liver disease and type 2 diabetes mellitus in different body mass index categories: A bidirectional Mendelian randomization study[J]. Journal of Clinical Hepatology, 2024, 40(10): 1992-1999. doi: 10.12449/JCH241011 |
[6] | Kaihao DU, Lizhao HOU, Lanminghui LUO, Xiaoge DONG, Wei JIANG, Zhan WANG. Current status and prospects of the application of Mendelian randomization in pancreatic cancer research[J]. Journal of Clinical Hepatology, 2024, 40(10): 2127-2136. doi: 10.12449/JCH241033 |
[7] | Min LIU, Weijian CHEN, Zhengzhen ZHOU, Xiaomei QIN, Rong WEN, Nan JIANG, Linzhi KUANG, Taiqing ZHENG, Liqiong ZHANG, Shuangjie LI. Histopathological characteristics of the liver in children with non-alcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2023, 39(5): 1144-1149. doi: 10.3969/j.issn.1001-5256.2023.05.021 |
[8] | Zhenqi LI, Ning DU, Hongyang He. Association between primary sclerosing cholangitis and the risk of colorectal cancer: A two-sample Mendelian randomization study[J]. Journal of Clinical Hepatology, 2023, 39(3): 567-572. doi: 10.3969/j.issn.1001-5256.2023.03.013 |
[9] | Cuiping SHAO, Youqing XU. Association of serum uric acid-to-creatinine ratio with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(10): 2348-2351. doi: 10.3969/j.issn.1001-5256.2021.10.018 |
[10] | Pei MEI, Zhengle ZHANG, Jing TAO. Association of nonalcoholic fatty liver disease with the severity of hyperlipidemic acute pancreatitis[J]. Journal of Clinical Hepatology, 2021, 37(1): 94-98. doi: 10.3969/j.issn.1001-5256.2021.01.019 |
[11] | Chuan LiXue, Chang Jiang, Zhao JinHan, Li LuoHua, Yang XuYao, Yu Di. Association between nonalcoholic fatty liver disease and colorectal adenomatous polyps[J]. Journal of Clinical Hepatology, 2020, 36(6): 1299-1303. doi: 10.3969/j.issn.1001-5256.2020.06.022 |
[12] | Wang XiangHong, Ma BaoHua, Zou XiuLan, Yao KeCheng, He Qian. Association between nonalcoholic fatty liver disease and epicardial adipose tissue: A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(6): 1304-1309. doi: 10.3969/j.issn.1001-5256.2020.06.023 |
[13] | FENG Gong, YAN QinQin, HE Na, MI Man. From nonalcoholic fatty liver disease to metabolic fatty liver disease:An analysis based on disease heterogeneity[J]. Journal of Clinical Hepatology, 2020, 36(11): 2597-2600. doi: 10.3969/j.issn.1001-5256.2020.11.045 |
[14] | Huang HaiYan, Wei RongXin, He GuangYing, Ceng HuiYuan. Prevalence of nonalcoholic fatty liver disease in taxi drivers in Shenzhen,China[J]. Journal of Clinical Hepatology, 2020, 36(3): 612-615. doi: 10.3969/j.issn.1001-5256.2020.03.028 |
[15] | Feng Gong, He Na, Mi Man, Li XuePing, Liu ManLing, Fan LiPing, Niu ChunYan. Risk factors for the coexistence of inflammatory bowel disease and nonalcoholic fatty liver disease: A Meta-analysis[J]. Journal of Clinical Hepatology, 2019, 35(4): 835-839. doi: 10.3969/j.issn.1001-5256.2019.04.025 |
[16] | Huang ZhiPeng, Jiang JianJia, Huang ZiCheng, Guo GuiYuan, Zhou APei, Liu XiaoQiang. Risk factors of nonalcoholic fatty liver disease with a normal visceral adipose tissue area[J]. Journal of Clinical Hepatology, 2019, 35(5): 1061-1064. doi: 10.3969/j.issn.1001-5256.2019.05.025 |
[17] | Chu PeiLing, Wang Qi, Guo XiaoQing, Liu JinChun. Association between chemokines and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2019, 35(7): 1626-1628. doi: 10.3969/j.issn.1001-5256.2019.07.044 |
[18] | Hou Jie, Liu LiXin. Effect of probiotics in treatment of nonalcoholic fatty liver disease: A Meta-analysis[J]. Journal of Clinical Hepatology, 2018, 34(12): 2624-2630. doi: 10.3969/j.issn.1001-5256.2018.12.023 |
[19] | Chen ZhiHui, Zhang ShiRong, Sun WenJing, Wen LiangZhi, Liu KaiJun, Guo Yan, Wei YanLing, Wang Bin, Gu XiaoHong, Chen DongFeng. A clinical study of pulmonary function changes in patients with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2018, 34(4): 825-828. doi: 10.3969/j.issn.1001-5256.2018.04.026 |
[20] | Wang Yan, Hou JinLin. Hepatic fibrosis in nonalcoholic fatty liver disease and its quantitative assessment[J]. Journal of Clinical Hepatology, 2017, 33(12): 2296-2302. doi: 10.3969/j.issn.1001-5256.2017.12.008 |